Harvard Perspectives on Prostate Disease

Advances and breakthroughs in prostate disease

Reviewed by Per-Anders Abrahamsson, M.D., Ph.D.

Advances in the understanding and treatment of prostate disease are constantly being reported in scientific meetings and peer-reviewed publications. What follows are some of the most interesting recent findings, placed in context by Per-Anders Abrahamsson, M.D., Ph.D., a member of Perspectives' editorial and advisory board, who in 2007 was elected Secretary General of the European Association of Urology, the leading professional organization overseas.

Initial PSA tests can't distinguish lethal prostate cancers

A separate group of Swedish researchers report that PSA levels measured within two years of a prostate cancer diagnosis provide no indication of which cancers are lethal and which are indolent. This finding increases the challenges faced by men diagnosed with early-stage prostate cancer who are considering active surveillance.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »